Gemelli Biotech IBS-Smart study finds lower diagnostic costs in patients with suspected IBS
Gemelli Biotech’s IBS-Smart and Trio-Smart were linked to lower captured diagnostic costs in a 219-patient IBS study, but causality remains unproven.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Biomerica’s responder data raises new questions about diet-driven IBS management
Biomerica reports real-world IBS responder data and Medicare coverage. Explore what this means for adoption, reimbursement, and competition.